RPRX - CIK 0001802768
The table below shows Royalty Pharma plc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | -$1.87B | -$2.76B |
| Dividends paid | - | - | - | - | - | - |
Royalty Pharma plc reported operating cash flow of $2.49B for fiscal year 2025. That is down 10.1% from $2.77B in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from $1.62B (FY 2018) to $2.49B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $1.23B | $229.65M | $304.76M | $0.00 | $0.00 | $0.00 |
| Financing cash flow | -$1.19B | $361.14M | -$2.15B | -$944.86M | $385.11M | $1.49B |